Ramucirumab and its use in gastric cancer treatment
- Autori: Bronte, G.; Galvano, A.; Cicero, G.; Passiglia, F.; Rolfo, C.; Bazan, V.; Russo, A.
- Anno di pubblicazione: 2014
- Tipologia: Articolo in rivista (Articolo in rivista)
- Parole Chiave: Angiogenesis; Gastroesophageal junction cancer; Metastatic gastric cancer; Monoclonal antibody; Ramucirumab; VEGF receptors; Pharmacology; Pharmacology (medical)
- OA Link: http://hdl.handle.net/10447/200965
The inhibition of the mechanisms of tumor neo-angiogenesis represents a milestone that in the last 10 years has seen the advent of numerous molecules to target action against the vascular endothelial growth factor (VEGF). More recently, new molecules have been developed that inhibit tumor spread by the blockade of specific VEGF receptors (VEGFRs), thereby preventing the binding of a ligand to its receptor and the cascade of proliferative events downstream. Ramucirumab is a fully humanized IgG1 monoclonal antibody that performs its action by blocking the isoform 2 of the VEGF receptor (VEGFR-2). Numerous preclinical and clinical studies have demonstrated its activity in several solid tumors, demonstrating a remarkable efficacy in terms of progression-free survival and overall survival in addition to a favorable toxicity profile. This review analyzes in detail the role of ramucirumab in the treatment of advanced gastric and gastroesophageal junction cancers.